Aphria (TSX:APH) announced the first completed shipment of cannabis oils to its Argentina-based subsidiary, ABP, as part of a clinical study looking to treat refractory epilepsy in children conducted by to Hospital de Pediatria Garrahan.
As quoted in the press release:
As a well-established and successful pharmaceutical import and distribution company, ABP was granted the first permit issued by the Argentina Ministry of Health for the import of pharmaceutical-grade medical cannabis. The Argentinean Company has been forging a reputation as a champion for the research and clinical study of medical cannabis, including through its partnership with the Hospital, one of the most recognized and credible medical institutions in South America.
The clinical study, which involves 100 patients and will be conducted over 2.5 years, will be one of the foundational global scientific and medical studies of its kind focused on treating refractory epilepsy in children. Medical researchers will conduct a pharmacokinetics study of the Rideau product, which will help optimize the ideal dosage in future patients. Top neurologists and pediatric specialists from around the country will participate and, with the support of ABP and Aphria, will receive training and support to be able to train and educate a network of doctors throughout Argentina.